Skip Ribbon Commands
Skip to main content

Endocrine Disruptor Testing Upgrades from EU: Stewardship and Substitution Implications

Friday, September 28 | 9:30 AM – 10:30 AM

Learning Level: Experienced | Topic: Global Regulations

The European Commission issued recommendations in 2018 expanding testing guidelines to address endocrine endpoints not analyzed in current standardized tests.  Additionally, the EU designation of products as having endocrine disrupting properties has now progressed to formal listings as Substances of Very High Concern, despite ongoing challenges to the criteria defining this hazard.  For product stewards, this designation regarding products or ingredients creates business implications due to public perception about this hazard and the carry-over impacts for GHS and other country markets once the EU designates a substance an endocrine disruptor.  This session will provide an update on pressures for costly additional testing and a team-based case study exercise will be used.

Learning Objectives

  1. Recognize the stewardship challenges of having products or ingredients labeled as endocrine disruptors by the EU.
  2. Understand scientific gaps creating motivation for additional testing recommendations.
  3. Explain the relative advantages and limitations of additional mammalian versus in vitro testing approaches.
Robert DeMott, Principal Toxicologist, Ramboll
Robert Skoglund, Director, Product Stewardship and Regulatory Affairs, Covestro